American Journal of Hematology

Article	Citations
Clinical events in a long‐term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea	371
Clonal hematopoiesis in unexplained cytopenias	327
Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor‐derived myelodysplastic syndrome using single‐cell multi‐omics analysis	228
	201
The latest insights into rare blood disorders: Diagnosis and treatment strategies	148
Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia	141
Complete response to pembrolizumab and radiation in a patient with HIV‐negative, EBV‐positive plasmablastic lymphoma	137
Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications	131
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	123
Issue Information	116
Congenital X‐linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6	103
NPM1‐mutated myeloid neoplasm with low percentage of blasts	88
Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent	85
Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry	81
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	81
Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients	70
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	69
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	62
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia	61
Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection	60
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	59
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease	56
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	55
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery	55
Rainer Prohaska (1943–2022)	51

Clinical impact of cytomorphology in mast cell leukemia	50
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?	49
Sickle cell allele HBB‐rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa	48
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma	46
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	46
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1	44
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	43
NOTCH1 Mutations Are Associated With Therapy‐Resistance in Patients With B‐Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies	42
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	42
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity‐score matched analysis	40
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	40
A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single i	39
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON	38
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	37
Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study	37
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials	36
Risk Factors and Prognostic Markers for Posterior Reversible Encephalopathy Syndrome in Patients With Thalassemia Major After Allogeneic Hematopoietic Stem Cell Transplantation	36
	34
Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia	34
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia	33
Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International	33
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle	33
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	33
Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosis	33
Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia	33
Acute Epstein‐Barr virus associated haemophagocytosis in an Asian female: What is the diagnosis?	32
Granular Mott cells in multiple myeloma	32
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores	31
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	31
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization	31
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	31
Issue Information	30
Diagnosis of histiocytic sarcoma by bone marrow aspiration	30
Occult recurrent breast cancer masquerading as thrombotic thrombocytopenic purpura	30
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	29
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	29
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	29
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	29
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception	29
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	29
Fetal hemoglobin per erythrocyte (HbF/F‐cell) after gene therapy for sickle cell anemia	29
Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells	28
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	28
	28
Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease	27
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	27
Breast implant‐associated anaplastic large cell lymphoma	27
Acute thrombocytopenia suggesting thrombotic microangiopathy	27
Oligoclonal gamma‐delta T cell expansion in response to Ehrlichia infection	27
An unusual lymphoma involving the GI tract and bone marrow	27

Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	26
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	25
Making a virtue out of an evil: Are red blood cells from chronic mountain sickness patients eligible for transfusions?	25
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes fr	25
Novel germline JAK2R715T mutation causing PV‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon	25
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications	25
Issue Information	25
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency	25
Issue Information	24
Pretreatment clinical and genetic factors predict early post‐treatment mortality in fit AML patients following induction	24
Is ≥ 100% the magic number to rule out the laboratory diagnosis of von Willebrand disease based on initial testing?	24
Clinical characteristics of cytomegalovirus‐positive pediatric acute lymphoblastic leukemia at diagnosis	24
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia	24
Issue Information	24
Erythropoietin‐secreting metanephric adenoma presenting as erythrocytosis	23
Follicular lymphoma: 2023 update on diagnosis and management	23
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies	23
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	23
Teclistamab in patients with multiple myeloma and impaired renal function	23
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis	23
A newly identified ferritin L‐subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia	22
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age	22
Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplast	22
Megakaryocyte morphology with GATA2 germline mutation	22
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma	22
Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact	22
Daratumumab monotherapy for relapsed POEMS syndrome	22
Bone marrow granulomatous reaction to silicone from breast implants	22
Increased transferrin protects from thrombosis in Chuvash erythrocytosis	22
Risk of infection in MPN patients in the era of Covid‐19: A prospective multicenter study of 257 patients from the CML‐MPN Quebec Rese	21
Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia	21
A rare case of catastrophic antiphospholipid syndrome triggered by estrogen‐containing oral contraceptives in a patient with double heterozygous factor V Leiden and prothrombin G20210A muta	21
Hematological support of patients with significant anemia who decline red blood cell blood transfusion	21
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO t	21
Issue Information	21
	21
Circulating rhabdoid tumor cells in the peripheral blood of a neonate	20
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	20
Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?	20
Issue Information	20
Issue Information	20
Multiple myeloma with central nervous system relapse presenting as right pupil‐sparing complete third nerve palsy	20
Self‐pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas	20
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	20
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?	19
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	19
Severe SARS‐CoV‐2 infection in rituximab‐treated patients with autoimmune cytopenia: A multicenter observational study	19
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher	19
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	19
Unraveling the mystery of the spleen	19
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	19
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic s	19
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan	19
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia	19
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy	19
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	18
The transcriptome‐wide landscape of molecular subtype‐specific mRNA expression profiles in acute myeloid leukemia	18
It's More Than Complex: Further Insights Into TP53 in MPN	18
Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients	18
Pseudoreticulocytosis in a patient with myelodysplastic syndrome	18
Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms	18
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management	17
Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy	17
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	17
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, mu	17
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience	17
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study	17
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion	17
Cardiac effects 2 years after successful non‐myeloablative human leukocyte antigen‐matched related donor hematopoietic cell transplants in sickle cell disease	17
Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia	17
CD19‐negative relapse in adult patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia following treatment with blinatumomab‐a post hoc analysis	17
Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis	17
Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID‐19 recovery	16
Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy	16
Long‐term risk of venous thromboembolism among patients with gastrointestinal non‐neoplastic and neoplastic diseases: A prospective cohort study of 484 211 individuals	16
Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?	16
Artificial intelligence generated leukemia cell images	16
Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes	16
BNT162b2 mRNA SARS‐CoV‐2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single‐arm, longitudinal study	16
SARS‐CoV‐2 infection in patients with β‐thalassemia: Experience from Lebanon	16

Ruxolitinib for refractory large granular lymphocyte leukemia	16
Single‐agent daratumumab for refractory POEMS syndrome	15
Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets	15
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis	15
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the i	15
Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis	15
Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia	15
Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)	15
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors	15
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab	15
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts	15
Peripheral blood cells vacuoles in VEXAS syndrome	14
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell	14
Unselected donor‐derived hematopoietic stem cells boost for Chimeric Antigen Receptor T‐cell associated hematotoxicity	14
Transcranial doppler velocity in iron‐deficient Nigerian children with sickle cell anemia	14
Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy	14
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	14
Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)	14
Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis	14
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors	14
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study	14
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib	14
Epidemiology of clinically significant forms of alpha‐ and beta‐thalassemia: A global map of evidence and gaps	14
An integrated therapeutic approach to sickle cell disease management beyond infancy	14
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies	14
	14
A framework for the clinical implementation of optical genome mapping in hematologic malignancies	14
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	14
Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy	13
Thrombopoietin mimetic‐induced bone marrow fibrosis	13
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy	13
Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial	13
The invisible lifeline: Intricacies of the global plasma supply	13
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	13
Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel	13
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA	13
2021 update on clinical trials in β‐thalassemia	13
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study	13
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States	13
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	13
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma	13
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	13
Trial designs and endpoints for immune therapies in multiple myeloma	13
The cognitive age in medicine: Artificial intelligence, large language models, and iterative intelligence	13
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia	12
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	12
A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia	12
Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study	12
Pituitary apoplexy in acute promyelocytic leukemia	12
At what COST?: A prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders	12
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions	12
A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia	12
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	12
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma	12
Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain	12
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study	12
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	12
A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer	12
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	12
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	12
Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study	12
Are veterans at increased risk of myeloproliferative neoplasms?	12
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	12
Issue Information	12
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	12
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	11
Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real‐world study in China	11
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	11
An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine	11
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	11
Intranasal fentanyl works—Why are we not using it more to treat acute pain in sickle cell disease?	11
Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse	11
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	11
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management	11
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	11
Prognostic significance of early acute splenic sequestration in children with severe sickle cell genotypes: A comprehensive longitudinal neonatal cohort study	11
Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease	11
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	11
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia	11
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria	11
Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia	11
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management	11
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot	11
The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms	11
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	11
Hereditary stomatocytosis in the general population: A genetically based prevalence estimate from a 109 039 individual Danish cohort	11
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targeting	11
Pseudo‐Chédiak–Higashi anomaly in acute myeloid leukemia	11
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	11
Bispecific T‐cell engagers for treatment of multiple myeloma	11
Molecular and clinicopathologic characterization of pediatric histiocytoses	11
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation	11
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis	11
Real‐world Big‐data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset	11
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	11